Advertisement

Picture EBD Group BioPharm America 2017 BPA Boston MA Startup September 600x60px
Document › Details

AstraZeneca plc. (5/1/17). "Presss Release: AstraZeneca’s Imfinzi (durvalumab) Receives US FDA Accelerated Approval for Previously Treated Patients with Advanced Bladder Cancer".

Region Region United States (USA)
Organisations Organisation MedImmune Inc. (Nasdaq: MEDI)
  Today MedImmune (biologics division of AstraZeneca)
  Group AstraZeneca (Group)
  Organisation 2 FDA (US Food and Drug Administration)
  Group United States (govt)
Products Product Imfinzi®
  Product 2 clinical research
Person Person Soriot, Pascal (AstraZeneca 201210– CEO before Roche COO Pharma Div before Genentech CEO)
     


   
Record changed: 2017-07-02

Advertisement

Picture EBD Group Bio-Europe 2017 BEU Berlin Germany November 600x60px

More documents for AstraZeneca (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture BIO Deutschland EBDC 2017 Heidelberg 600x60px




» top

Advertisements

Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture EBD Group Bio-Europe 2017 BEU Berlin Germany November 120x80px Picture BIO Deutschland EBDC 2017 Heidelberg 120x240px Picture EBD Group BioPharm America 2017 BPA Boston MA Startup September 120x80px Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px Banner Fairtec GmbH Solutions for Smarter Business Events Exhibitions 120x120px Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture BIO Deutschland EBDC 2017 Heidelberg 120x240px Picture EBD Group BioPharm America 2017 BPA Boston MA Startup September 120x80px Picture EBD Group Bio-Europe 2017 BEU Berlin Germany November 120x80px